Povećani ukupni TGF-β1 nivoi u plazmi i deregulisana IgA - IgM interakcija kod hronične opstruktivne bolesti pluća

  • Rajna Minic Institute of Virology, Vaccines and sera, Torlak
  • Olivera Đukić Katedra za Bromatologiju, Farmaceutski fakultet Univerzitet u Beogradu
  • Dejana Kosanović Grupa za Imunologiju, Institut za medicinska istraživanja, Univerzitet u Beogradu, Institut od nacionalnog značaja za Republiku Srbiju
  • Dejan Žujović Gradski zavod za plućne bolesti i tuberkulozu
  • Aleksandra Ilić Medicinski fakultet Univerzitet u Beogradu
  • Marko Panić Institut za Virusologiju, vakcine i serume, Torlak
  • Brižita Đorđević Katedra za Bromatologiju, Farmaceutski fakultet Univerzitet u Beogradu
DOI: https://doi.org/10.5937/jomb0-57461

Sažetak


Uvod: Hronična opstruktivna plućna bolest (HOBP) se eksprimira kao opstrukcija malih disajnih puteva i uključuje iznenadno i značajno pogoršanje simptoma, ponekad uzrokovano infekcijama.

Metode: Pacijenti sa HOBP (n=38) i akutnim bronhitisom (AB, n=35) su grupisani na osnovu starosti i plazma je uzorkovana u dve vremenske tačke: tokom pogoršanja/infekcije i nakon 30 dana. Mereni su različiti biomarkeri, uključujući ukupne nivoe TGF- β1 u plazmi, ukupni IgA, ukupni IgM i nivoi Pseudomonas aeruginosa specifičnih IgA antitela.

Rezultati: Povećani nivoi TGF- β1 su otkriveni kod pacijenata sa HOBP, bez značajne promene nakon 30 dana. Značajno sniženje ukupnog nivoa IgA u plazmi je primećeno kod pacijenata sa HOBP tridesetog dana. Nije primećena značajna razlika u specifičnim nivoima P. aeruginosa IgA između dve grupe pacijenata, ni tokom vremena. Zanimljivo je da je korelacija između ukupnih nivoa IgM i IgA bila odsutna kod pacijenata sa HOBP. Dok je pozitivna korelacija između starosti i nivoa IgA postojala kod pacijenata sa akutnim bronhitisom, ova korelacija je bila negativna kod pacijenata sa HOBP. Uočena je značajna korelacija između ukupnog IgA i P. aeruginosa specifičnog IgA kod pacijenata sa akutnim bronhitisom. S druge strane, pacijenti sa HOBP nisu pokazali nikakvu korelaciju pri t=0, ali je uočena korelacija između ukupnog IgA i P. aeruginosa specifičnog IgA1 pri t=30, što implicira da je rezolucija pogoršanja praćena konsolidacijom, tj. odgovarajućom stabilizacijom nivoa P. aeruginosa specifičnog IgA kod pacijenata sa COPD.

Zaključak: Ovde izveštavamo o deregulisanoj IgA - IgM osi kod HOBP i pozivamo na izvođenje temeljnih studija humoralnog imunskog sistema, većeg obima.

 

Reference

1. Orozco RJ, Rodriguez D, Hunter K, Roy S. The 2021 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines and the outpatient management: Examining physician adherence and its effects on patient outcome. J Family Med Prim Care. 2024;13:736-742. https://doi.org/10.4103/jfmpc.jfmpc_1397_23

2. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977; 1:1645-8. https://doi.org/10.1136/bmj.1.6077.1645.

3. Hnizdo E, Sullivan PA, Bang KM, Wagner G. Airflow obstruction attributable to work in industry and occupation among U.S. race/ethnic groups: a study of NHANES III data. Am J Ind Med. 2004;46:126-35. https://doi.org/10.1002/ajim.20042

4. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, Romieu I, Silverman EK, Balmes JR; Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:693-718. https://doi.org/10.1164/rccm.200811-1757ST.

5. Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer. 2015 ;90:121-7. https://doi.org/10.1016/j.lungcan.2015.08.017

6. Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1753465817750524. https://doi.org/10.1177/1753465817750524.

7. GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the Global Burden of Disease Study 2019. EClinicalMedicine. 2023;59:101936. https://doi.org/10.1016/j.eclinm.2023.101936

8. Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin Proc. 2018;93:1488-1502. https://doi.org/10.1016/j.mayocp.2018.05.026.

9. Evans, M. D., Pryor, W. A. Cigarette smoking, emphysema, and damage to α1-proteinase inhibitor. American Journal of Physiology - Lung Cellular and Molecular Physiology 1994;266: L593-L611. https://doi.org/10.1152/ajplung.1994.266.6.l593

10. Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res. 2001;2:20-6. https://doi.org/10.1186/rr34.

11. Sharp RR, de Serres F, Newman L, Sandhaus RA, Walsh JW, Hood E, Harry GJ. Environmental, occupational, and genetic risk factors for alpha-1 antitrypsin deficiency. Environ Health Perspect. 2003;111:1749-52. https://doi.org/10.1289/ehp.6325.

12. Meseeha M, Sankari A, Attia M. Alpha-1 Antitrypsin Deficiency. [Updated 2024 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK442030/

13. Königshoff M, Kneidinger N, Eickelberg O. TGF-beta signaling in COPD: deciphering genetic and cellular susceptibilities for future therapeutic regimen. Swiss Med Wkly. 2009;139:554-63. https://doi.org/10.4414/smw.2009.12528

14. Wu L, Chau J, Young RP, Pokorny V, Mills GD, Hopkins R, McLean L, Black PN. Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax. 2004;59:126-9. https://doi.org/10.1136/thorax.2003.005769

15. Celedón JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, DeMeo DL, et al. The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet. 2004;13:1649-56. https://doi.org/10.1093/hmg/ddh171.

16. Putcha N, Paul GG, Azar A, Wise RA, O'Neal WK, Dransfield MT, et al. Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS. PLoS One. 2018;13:e0194924. https://doi.org/10.1371/journal.pone.0194924

17. Pilette C, Godding V, Kiss R, Delos M, Verbeken E, Decaestecker C, et al. Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:185-94. https://doi.org/10.1164/ajrccm.163.1.9912137

18. Polosukhin VV, Cates JM, Lawson WE, Zaynagetdinov R, Milstone AP, Massion PP, et al. Bronchial secretory immunoglobulin a deficiency correlates with airway inflammation and progression of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184:317-27. https://doi.org/10.1164/rccm.201010-1629OC

19. Gohy ST, Detry BR, Lecocq M, Bouzin C, Weynand BA, Amatngalim GD, et al. Polymeric immunoglobulin receptor down-regulation in chronic obstructive pulmonary disease. Persistence in the cultured epithelium and role of transforming growth factor-β. Am J Respir Crit Care Med. 2014;190:509-21. https://doi.org/10.1164/rccm.201311-1971OC

20. Ladjemi MZ, Lecocq M, Weynand B, Bowen H, Gould HJ, Van Snick J, et al. Increased IgA production by B-cells in COPD via lung epithelial interleukin-6 and TACI pathways. Eur Respir J. 2015;45:980-93. https://doi.org/10.1183/09031936.00063914

21. Sánchez Montalvo A, Gohy S, Rombaux P, Pilette C, Hox V. The Role of IgA in Chronic Upper Airway Disease: Friend or Foe? Front Allergy. 2022;3:852546. https://doi.org/10.3389/falgy.2022.852546

22. Millares L, Martí S, Ardanuy C, Liñares J, Santos S, Dorca J, et al. Specific IgA against Pseudomonas aeruginosa in severe COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2807-2811. https://doi.org/10.2147/COPD.S141701

23. Martínez-Solano L, Macia MD, Fajardo A, Oliver A, Martinez JL. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis. 2008;47:1526-1533. https://doi.org/10.1086/593186

24. Maurice NM, Bedi B, Sadikot RT. Pseudomonas aeruginosa Biofilms: Host Response and Clinical Implications in Lung Infections. Am J Respir Cell Mol Biol. 2018;58:428-439. https://doi.org/10.1165/rcmb.2017-0321TR

25. Rodrigo-Troyano A, Melo V, Marcos PJ, Laserna E, Peiro M, Suarez-Cuartin G, et al. Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease Patients with Frequent Hospitalized Exacerbations: A Prospective Multicentre Study. Respiration. 2018;96:417-424. https://doi.org/10.1159/000490190.

26. Eklöf J, Sørensen R, Ingebrigtsen TS, Sivapalan P, Achir I, Boel JB, et al. Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients. Clin Microbiol Infect. 2020;26:227-234. https://doi.org/10.1016/j.cmi.2019.06.011.


27. Minić R, Papić Z, Đorđević B, Michaličkova D, Ilić V, Mathiesen G, et al. Profiling of microorganism-binding serum antibody specificities in professional athletes. PLoS One. 2018 Sep 25;13(9):e0203665. https://doi.org/10.1371/journal.pone.0203665

28. Knežević S, Kosanović D, Dragačević L, Živković I, Ilić V, Hajduković L, et al. Age and gender associated changes in immunoglobulin subclass levels specific to S. pneumoniae, serotype 1. Comp Immunol Microbiol Infect Dis. 2022;87:101834. https://doi.org/10.1016/j.cimid.2022.101834.

29. van Eeden SF, Hogg JC. Immune-Modulation in Chronic Obstructive Pulmonary Disease: Current Concepts and Future Strategies. Respiration. 2020;99:550-565. https://doi.org/10.1159/000502261

30. Mahmood MQ, Reid D, Ward C, et al. Transforming growth factor (TGF) β1 and Smad signalling pathways: A likely key to EMT-associated COPD pathogenesis. Respirology. 2017;22:133-140. https://doi.org/10.1111/resp.12882

31. Moon J, Yoon JY, Yang JH, Kwon HH, Min S, Suh DH. Atrophic acne scar: a process from altered metabolism of elastic fibres and collagen fibres based on transforming growth factor-β1 signalling. Br J Dermatol. 2019 Dec;181(6):1226-1237. https://doi.org/10.1111/bjd.17851.

32. Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, et al. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). American journal of respiratory and critical care medicine. 2001;163(6):1476–83. https://doi.org/10.1164/ajrccm.163.6.9908135

33. Togo S, Holz O, Liu X, Sugiura H, Kamio K, Wang X, et al. Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms. American journal of respiratory and critical care medicine. 2008;178(3):248–60. https://doi.org/10.1164/rccm.200706-929OC

34. Brandtzaeg, P. (2003). Immunology of tonsils and adenoids: everything the ENT surgeon needs to know. International Congress Series, 1254. https://doi.org/10.1016/s0531-5131(03)00964-6

35. Zhou, L., & Sonnenberg, G. F. (2018). Essential immunologic orchestrators of intestinal homeostasis. Science Immunology, 3(20). https://doi.org/10.1126/sciimmunol.aao1605

36. Pilette C, Godding V, Kiss R, Delos M, Verbeken E, Decaestecker C, De Paepe K, Vaerman JP, Decramer M, Sibille Y. Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Jan;163(1):185-94. https://doi.org/10.1164/ajrccm.163.1.9912137.

37. Gomez-Olivas JD, Oscullo G, Martinez-Garcia MA. Isolation of Pseudomonas aeruginosa in Stable Chronic Obstructive Pulmonary Disease Patients-Should We Treat It?. J Clin Med. 2023;12(15):5054. https://doi.org/10.3390/jcm12155054

38. Kwok WC, Tam TCC, Chau CH, Lam FM, Ho JCM. Clinical Implications of Pseudomonas Aeruginosa Colonization in Chronic Obstructive Pulmonary Disease Patients. Chronic Obstr Pulm Dis. Published online February 5, 2025. https://doi.org/10.15326/jcopdf.2024.0582

39. Rello J, Krenn CG, Locker G, et al. A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients. Crit Care. 2017;21(1):22. Published 2017 Feb 4. https://doi.org/10.1186/s13054-017-1601-9

40. Adlbrecht C, Wurm R, Depuydt P, et al. Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial. Crit Care. 2020;24(1):74. Published 2020 Mar 4. https://doi.org/10.1186/s13054-020-2792-z

41. Bhat, T. A., Panzica, L., Kalathil, S. G., & Thanavala, Y. (2015). Immune Dysfunction in Patients with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 12 Suppl 2(Suppl 2), S169–S175. https://doi.org/10.1513/AnnalsATS.201503-126AW
Objavljeno
2025/11/25
Broj časopisa
Ahead of print
Rubrika
Original paper

Sva prava zadržana (c) 2025 Rajna Minic, Olivera Đukić, Dejana Kosanović, Dejan Žujović, Aleksandra Ilić, Marko Panić, Brižita Đorđević

Creative Commons License

Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.